On November 19, 2020 Syngene International and Deerfield Discovery and Development Corporation (3DC), the drug discovery and development subsidiary of Deerfield Management Company (Deerfield), reported that they have signed an agreement to collaborate to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation (Press release, Syngene International, NOV 19, 2020, View Source [SID1234571446]). This five-year collaboration unites the core skills of the investment management company Deerfield, through its drug discovery and development arm 3DC, and Syngene’s integrated drug discovery (IDD) services.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Syngene’s Managing Director and CEO, Jonathan Hunt, said: "Syngene will deliver fully integrated therapeutic discovery programs for 3DC. Syngene is an industry-leading collaboration partner for pharma, biotech, and venture capital firms, and we are delighted to have 3DC as a major strategic partner. Their reputation for identifying highly promising science is a great fit with our ability to lead and deliver world-class scientific execution for their growing portfolio."
"This collaboration forms an important part of our execution strategy. When we identify a promising biological target, our goal is to discover and deliver the best possible therapeutic agent to the clinic as quickly and safely as possible," said Mike Foley, Ph.D., CEO of 3DC. "We believe the Syngene-Deerfield collaboration may provide critical new therapeutic options with pace and efficiency that could improve the lives of many patients."
3DC has selected Syngene as a key execution partner for a developing portfolio of molecular entities, spanning multiple therapeutic areas and modalities. The ultimate goal is to deliver much-needed benefit to patients suffering from serious, unmet medical needs through innovation, scale, quality, and speed-to-market.
The collaboration will start with immediate effect and is expected to run for an initial cycle of 5 years.